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Abstract
Background: Ovarian carcinomas, usually associated with sex hormones dysregulation, are the leading cause of
gynecological neoplastic death. In normal ovaries, hormones play a central role in regulating cell proliferation,
differentiation, and apoptosis. On the other hand, hormonal alterations also play a variety of roles in cancer.
Stimulation by sex hormones potentially affects gene expression, invasiveness, cell growth and angiogenesis.
Proteases of the “a disintegrin and metalloproteinase with thrombospondin motifs” (ADAMTS) family are secreted
by different cell types and become involved in collagen processing, cleavage of the proteoglycan matrix, and
angiogenesis. We evaluated whether sex hormones affect ADAMTS 1 and 4 expression in ovarian cancer cells.
Methods: We analysed mRNA and protein levels in human ovarian tumor cells with different degrees of malignancy,
NIH-OVCAR-3 and ES-2, that were treated or not with estrogen, testosterone and progesterone.
Results: Our results suggest that progesterone increases ADAMTS protein and mRNA levels in the lysates from ES-2
cells, and it increases ADAMTS protein in the lysates and conditioned media from NIH-OVCAR-3. Progesterone effects
were reversed by RU486 treatment.
Conclusion: We conclude that progesterone acts via the progesterone receptor to modulate ADAMTS 1 and 4 levels
in ovarian cancer cell lines.
Keywords: Ovarian cancer, Extracellular matrix, Matrix metalloproteinases, ADAMTS, Hormones, Androgen receptor,
Estrogen receptor and Progesterone receptor, ES-2, NIH-OVCAR-3
Background
Ovarian cancer represents the most lethal malignancy of
the female reproductive system [1]. Poor prognosis for
women with late-stage disease results in large part from
therapy ineffectiveness [2].
In normal ovaries, hormones play a central role in
regulating cell proliferation, differentiation, and apoptosis.
However, hormonal alterations also play a role in ovarian
cancer, affecting gene expression, invasiveness, cell
growth, and angiogenesis [3].
Androgens constitute the major pre- and postmeno-
pausal ovarian hormonal product, and serve as required
substrates for estrogen synthesis. High androgen levels
correlate with increased risk of ovarian cancer develop-
ment. Moreover, the incidence of ovarian cancer in-
creases after the menopause, when androgens represent
the main steroids produced by the ovary [4, 5].
The corpus luteum secretes progesterone, a key com-
ponent in the regulation of female reproductive tissue
growth and development. In the ovary, progesterone
plays a central role in regulating ovulation and luteiniza-
tion via classical receptor-mediated pathways [6]. In
ovarian cancer, progesterone might protect against
tumor development [7].
Estradiol is predominantly responsible for secondary
sexual characteristics in women. Studies have shown that
estrogen stimulates growth of ovarian tumor cell lines
expressing estrogen receptors (ER) [8]. Epidemiological
studies have indicated that estrogen replacement therapy* Correspondence: vfreitas@usp.brCell and Developmental Biology Department, Biomedical Sciences Institute
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in postmenopausal women may increase ovarian cancer
incidence as well as mortality rates [9, 10].
Hormones also affect the tumor microenvironment,
composed of soluble factors and extracellular matrix (ECM)
molecules. The protease a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS) is an MMP-
related enzyme [11]. This protein has a multi-domain
structure and various functions, including collagen pro-
cessing, cleavage of the proteoglycan matrix [12], cleavage
of the von Willebrand factor, as well as roles in inflamma-
tion, organogenesis and fertility [13, 14]. These proteases
also have anti-angiogenic effects [15–17], and a review of
the literature shows that the expression of ADAMTS1 is
decreased in different types of cancer, including ovarian
cancer [18], what indicates an important role this protease
in ovarian health. Furthermore ADAMTS 1 mutations
may affect the outcome of ovarian cancers [19].
In the normal ovary, during the LH-induced process
of ovulation, the release of a mature oocyte through the
surface epithelium requires remodeling of the ovarian
ECM. This process is associated with cell-specific expres-
sion of numerous proteases [20]. Among these proteins,
the normal ovary expresses, for example, ADAMTS 1 [21]
and 4 [22]. Sex hormones represent potentially important
regulators of ADAMTS expression [23]. However, the
correlation between steroid hormones and ADAMTS
expression has not been assessed in ovarian cancer models.
In this study, we evaluated the levels of hormone re-
ceptors and the effects of testosterone, progesterone and
estrogen on the expression of ADAMTS 1 and 4 mRNA
and protein in human ovarian tumor cells with different
degrees of malignancy including NIH-OVCAR-3 and
ES-2.
Results
NIH-OVCAR-3 and ES-2 cells expression of estrogen,
progesterone and testosterone receptors
Receptors for androgen (AR) and estrogen (ER) were
present in the nucleus of the more differentiated cell line,
NIH-OVCAR-3, as observed by immunofluorescence,
however, they also appear distributed in the cell cytoplasm
(Fig. 1a, b). On the other hand, progesterone receptor
(PR) was present mostly in the cell cytoplasm (Fig. 1c).
Western blot after cell fractionation showed that PR was
observed mostly in the cell cytoplasm but also at the nu-
cleus, while ER and AR are present only in the nucleus
(Fig. 1g).
In the less differentiated cell line, ES-2, immunofluor-
escence showed that receptors distribution was similar
to NIH-OVCAR-3, AR and ER mostly in the cell nucleus
(Fig. 1d, e) but PR was present in the cytoplasm and nu-
cleus (Fig. 1f ). Western blot after cell fractionation cor-
roborated immunofluorescence findings, since the same
pattern was observed, ER and AR are present mostly in
the cell nucleus but also in the cytoplasm and PR present
mostly in the cell cytoplasm but a smaller amount in the
cell nucleus (Fig. 1g).
Hormone treatments do not affect cell viability but
differentially affect mRNA and protein expression of
ADAMTS 1 and 4
The hormones tested are known to increase proliferation
of other cell lines. Neither cell line, NIH-OVCAR-3 or
ES-2, reacted to hormone treatments with changes in
viability in comparison to the respective serum-free con-
trols (Fig. 2a, b).
Hormone treatment did not significantly alter ADAMTS 1
mRNA expression in the more differentiated cell line,
NIH-OVCAR-3 (Fig. 2c). Only testosterone treatment,
in comparison to control, induced a significant decrease
in ADAMTS 4 gene expression in NIH-OVCAR-3 cells
(Fig. 2d). In the less differentiated cell line, ES-2,
mRNA levels of ADAMTS 1 and 4 were reduced by estro-
gen and testosterone treatment in comparison to control
(Fig. 2e, f ). We also observed an increase in the expression
of ADAMTS 1 and 4 mRNA in ES-2 cells treated with
progesterone in ES-2 (Fig. 2e, f ).
Protein levels of ADAMTS 1 and 4 presented a tendency
to increase when treated by progesterone in NIH-OVCAR-3
cell lysates (Fig. 3a–c). Analysis of the NIH-OVCAR-3
conditioned medium showed that progesterone treatment
increased ADAMTS 1 and 4 protein levels in comparison
to controls (Fig. 3d–f and S1a).
In ES-2 cells, progesterone induced ADAMTS 1 and 4
protein levels increase (Fig. 4a–d). Hormone treatments
had the same effect on ADAMTS 1 and 4 protein levels
in ES-2-conditioned media (Fig. 4e–g and Additional file 1:
Figure S1b). Addicionally, there was an increase in
ADAMTS 4 in the conditioned medium when ES-2 cells
were treated by testosterone (Fig. 4g).
RU486 reverses progesterone mediated induction of
ADAMTS 1 and 4 protein expression
To evaluate whether the progesterone induced increase
in ADAMTS 1 and 4 protein levels in NIH-OVCAR-3
and ES-2 cells resulted from activation of the progester-
one receptor, we conducted a set of experiments in which
the progesterone receptor antagonist RU486 was added to
the media with progesterone.
Co-treatment with RU486 showed decrease of
progesterone-mediated induction of ADAMTS 1 (Fig. 5a, c)
and 4 (Fig. 5b, d) in the cell lysate of NIH-OVCAR-3
cells. The progesterone receptor antagonist also reversed
the effects of progesterone on ADAMTS 1 protein levels
in NIH-OVCAR-3 conditioned media (Fig. 5e, f and
Additional file 1: Figure S1c), whereas no significant ef-
fects were observed regarding ADAMTS 4 (Fig. 5e, g).
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Fig. 1 (See legend on next page.)
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RU486 treatment reversed the progesterone effect on
ADAMTS 1 and 4 in ES-2 cells lysates (Fig. 6a–d). In
ES-2-conditioned media, progesterone treatment re-
sulted in an increase of expression of ADAMTS 1 and 4
compared to control (Fig. 6e–g and Additional file 1:
Figure S1d). However, treatment with the PR antagonist
RU486 was ineffective in reversing these effects (Fig. 6e–g
and Additional file 1: Figure S1d).
Discussion
Proteolytic modification of cell-surface proteins and
extracellular matrices represents a fundamental step for
a diverse array of biological and pathological processes,
including embryogenesis, wound healing, and cancer
metastasis [20]. In this study we observed ADAMTS 1,
65 kDa (fragmented or processed) in the cells conditioned
medium and ADAMTS 1, 110 kDa (full-length or unpro-
cessed) was detected in the cell lysate of both cell lines
studied. Full-length ADAMTS 1 has pro-tumor activity,
whereas the fragmented protein has anti-tumor activity.
Also, full length ADAMTS 1 increases tumor cell prolifer-
ation rates and accelerates tumor development through
the activity of its metalloproteinase domain [24]. With re-
gard to epigenetic mechanisms in ovarian carcinomas,
ADAMTS 1 gene has been described as not methylated
[25]. More recently, a comprehensive study showed that
members of the ADAMTS family, including ADAMTS 1,
present somatic mutations that are associated to chemo-
therapy outcome in ovarian cancer patients [19]. Con-
cerning ADAMTS 4, we observed that ADAMTS 4,
90 kDa (full-length or unprocessed) in the cell lysate
and ADAMTS 4, 62 kDa (fragmented or processed) is
detected in the conditioned medium of both ovarian
cancer cell lines studied. Other group has demonstrated
that full-length ADAMTS 4 promoted melanoma tumor
growth. In contrast, the C-terminal ancillary regions and
the full-length protein lacking catalytic activity inhibited
tumor growth [26]. Thus, ADAMTS 4 behaves similarly
to ADAMTS 1 in that it has both pro-and anti-
tumorigenic activities promoted depending on its form.
Here, we detected different forms of ADAMTS 1 and
ADAMTS 4 depending on cell localization. As expected
for an extracellular protease the processed or activated
form was found secreted in the cell’s conditioned medium.
MTT revealed that hormones, in the concentration
used here, did not alter cell viability of NIH-OVCAR-3
or ES-2 cell lines, when compared to serum-free control
group. Thus, changes in the levels of gene and protein
expression of proteases are unrelated to the increase or
decrease in cell number induced by hormones. The ES-2
cell line, when treated with estrogen or testosterone,
showed decreased mRNA levels of ADAMTS 1 and 4,
while progesterone treatment increased the mRNA levels
in both cell lines. At the protein level, progesterone in-
creased ADAMTS 1 and 4 expression in ES-2 cell lysates
and conditioned medium.
Regarding the cell line NIH-OVCAR-3, we observed
that testosterone treatment reduced the mRNA expression
of ADAMTS 4. Western blot analysis indicated that pro-
gesterone treatment induced increased of protein levels of
ADAMTS 1 in the conditioned medium. Despite the
increase in ADAMTS 1 protein expression induced by
progesterone, this hormone was not able to induce an
increase in ADAMTS 1 gene expression in the same
NIH-OVCAR-3 cell line. Northern blot analysis showed
that ADAMTS 1 gene expression reaches its maximum
levels after 12 h post hormone stimulation and this ex-
pression declined significantly during early luteal for-
mation [21]. In this work we analysed mRNA expression
after 24 h post-treatment and the ADAMTS 1 mRNA
levels could be decreased at this point. We also observed
that RU486 reversed the effects of progesterone on the
levels of ADAMTS 1 in the lysates from both cell lines and
ADAMTS 4 in ES-2 cells, which further suggests that pro-
gesterone acts directly through its receptor to increase the
expression of this proteases in ovarian cancer cell lines.
In the present study we observe that both NIH-OVCAR-3
and ES-2 cells express PR, mainly in the cytoplasm but also
in the nuclei. Considering that both cell lines express the
same PR pattern, we speculate that the absence of RU486 ef-
fect in decreasing ADAMTS 1 and 4 from the conditioned
medium stimulated by progesterone could be related to the
secretory pathway of these proteases in ES-2 cell line.
Previous studies have shown that progesterone is the
most potent regulator of ADAMTS gene expression
[23]. Progesterone elicits its physiological effects especially
through the activation of the progesterone receptor (PR)
[27]. Thus, progesterone-receptor-null mice fail to ovulate
and express markedly reduced levels of ADAMTS 1 [23].
(See figure on previous page.)
Fig. 1 Distribution of AR, ER and PR in NIH-OVCAR-3 and ES-2 cells. AR, ER and PR (red), nuclei (blue) and actin (green). Merge dots in magenta
indicate the colocalization of the receptors with the nucleus. In NIH-OVCAR-3 cells a Androgen receptor and b Estrogen receptor are mostly
in the nucleus, but also appears in cytoplasm. c Progesterone receptor is mostly found in the cell cytoplasm. In ES-2 cells d Androgen receptor and
e Estrogen receptor are also mainly in the cell nucleus. f Progesterone receptor is located in cytoplasm and nucleus. g Immunoblot of NIH-OVCAR-3 and
ES-2 cell fractions for receptors. In NIH-OVCAR-3 cells ER and AR are present in the nucleus, PR is present in both compartments, but mostly in the
cytosolic fraction. ES-2 cells present most of the AR and ER in the nuclear fraction and PR is preferentially in the cytosolic compartment. Scale bar:
20 μm. (C = cytosolic fraction, N = nuclear fraction)
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Physiologically the progesterone receptor (PR) gene is ac-
tivated by the action of luteinizing hormone (LH) in the
ovaries. Progesterone binds to its receptor in granulosa
cells, resulting in increased ADAMTS 1 [28, 29]. The
ADAMTS 1 gene does not have a progesterone responsive
element. Thus, PR-mediated induction of the ADAMTS
gene seems to occur indirectly through interactions of PR
with the transcriptional regulators C/EBPβ, NF1-like fac-
tor, and Sp1/3. In this sense, PR plays the role of an
ADAMTS 1 coregulator in granulosa cells [28]. The pro-
tective effects of progesterone could be mediated by the
nuclear progesterone receptor (n-Pr), which is gradually
Fig. 2 Cell viability and ADAMTS mRNA expression in NIH-OVCAR-3 and ES-2 cell lines, after hormone treatment. a and b MTT viability assay of
NIH-OVCAR-3 and ES-2 cell lines treated with 30 nM estrogen, 1 μM progesterone or 100 nM testosterone for 24 h compared to control. c and d
ADAMTS 1 and 4 mRNA expression assessed by qPCR in the lysates of NIH-OVCAR-3 cells. GAPDH was used as normalizer. e and f ADAMTS 1 and
4 mRNA expression assessed by qPCR in the cell lysates of ES-2 cells. GAPDH was used as normalizer. Differences among groups were considered
statistically significant when p≤ 0.05. Experiments were performed in triplicate
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lost with increasing ovarian cancer malignancy [30]. Here,
we observe that besides the differences in cell morphology
and behavior, NIH-OVCAR-3 and ES-2 have similar PR
expression and localization under the same circumstances
(without hormone treatment and phenol red) and the ef-
fects of progesterone were similar in both cell lines.
ADAMTS 1 and 4 have different functions depending
on their molecular conformation [24, 26] and they can bind
the vascular endothelial growth factor (VEGF). In the
ECM, ADAMTS 1 and 4 might sequester VEGF, preventing
it from binding to its cellular receptor, and ultimately lead-
ing to a decrease in cell migration and invasion rates
[26, 31]. Progesterone may exert part of its protective
effects against ovarian cancer by increasing ADAMTS 1
and 4, which in turn would decrease cell migration and
invasion. Further studies should focus on this hypothesis.
Conclusions
We conclude that progesterone acts via progesterone re-
ceptor to regulate ADAMTS 1 production and secretion
Fig. 3 ADAMTS 1 and 4 protein expression of NIH-OVCAR-3 cell lysates and conditioned medium, after hormone treatment. a Representative Western
blot of ADAMTS 1 and 4 in the lysates of NIH-OVCAR-3 cells treated with 30 nM estrogen (E), 1 μM progesterone (P), or 100 nM testosterone
(T), compared to control (C). β-actin was used as loading control. b and c ADAMTS 1 and 4 protein expression in the lysates of NIH-OVCAR-3 cells. d
Representative Western blot of ADAMTS 1 and 4 in the conditioned medium from NIH-OVCAR-2 cells. e and f ADAMTS 1 and 4 protein expression in
the conditioned medium from NIH-OVCAR-3 cells. Conditioned medium equal sample loading was confirmed by Pounceau S staining (Additional file 1:
Fig. S1a). Differences among groups were considered statistically significant when p≤ 0.05. Experiments were performed in triplicate
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Fig. 4 (See legend on next page.)
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by differentiated ovarian cancer cells (NIH-OVCAR-3)
and in less differentiated cancer cells (ES-2), progesterone
receptor inhibitor is able to decrease ADAMTS 1 and 4 in
the cell lysate but not in the conditioned medium of ES-2
cells.
Methods
Cell lines
The cell line NIH-OVCAR-3 is derived from an ovarian
adenocarcinoma and has epithelioid morphology. The
cell line ES-2 was developed from a clear cell carcinoma
Fig. 5 RU486 can rescue the increase of ADAMTS 1 induced by progesterone in NIH-OVCAR-3 conditioned medium. a and b Representative Western
blot of ADAMTS 1 and 4 in the lysates of NIH-OVCAR-3 cells treated with progesterone (P) or progesterone and RU486 (P + RU486) compared
to control (C). c and d ADAMTS 1 and 4 protein expression in the lysate of NIH-OVCAR-3 cells. e Representative Western blot of ADAMTS 1
and 4 in the conditioned medium from NIH-OVCAR-3 cells. f and g ADAMTS 1 and 4 protein expression in conditioned medium of NIH-OVCAR-3.
Conditioned medium equal sample loading was confirmed by Pounceau S staining (Additional file 1: Fig. S1c). Differences among groups were consid-
ered statistically significant when p≤ 0.05. Experiments were performed in triplicate
(See figure on previous page.)
Fig. 4 Progesterone induces increase of ADAMTS 1 and 4 in cell lysates and conditioned medium of ES-2 cell. a and c Representative Western
blot of ADAMTS 1 and 4 in the lysates of ES-2 cells treated with 30 nM estrogen (E), 1 μM progesterone (P) or 100 nM testosterone (T), compared
to control (C). β-actin was used as loading control. b and d ADAMTS 1 and 4 protein expression in the lysates of ES-2 cells. e Representative West-
ern blot of ADAMTS 1 and 4 in the conditioned medium from ES-2 cells. f and g ADAMTS 1 and 4 protein expression in the conditioned medium
from ES-2 cells. Conditioned medium equal sample loading was confirmed by Pounceau S staining (Additional file 1: Fig. S1b). Differences among
groups were considered statistically significant when p≤ 0.05. Experiments were performed in triplicate
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of the ovary and has a fusiform morphology. Cells were
obtained from the Cell Bank of Rio de Janeiro. ES-2 and
NIH-OVCAR-3 cells were cultured in Dulbecco’s Modi-
fied Eagle’s Medium-F12 (DMEM-F12, Sigma Chemical
Co, St. Louis, MO, USA) supplemented with 10 % fetal
bovine serum (FBS; Cultilab, Campinas, SP, Brazil). Cells
were maintained in 75 cm2 flasks in a humidified atmos-
phere of 5 % CO2 at 37 °C.
Immunofluorescence
Cells grown on glass coverslips was fixed in 4 % paraformal-
dehyde in phosphate-buffered saline (PBS) for 10 min,
rinsed and permeabilized with 0,5 % Triton X-100 (Sigma)
in PBS for 10 min, rinsed and blocked with Normal Goat
Serum (10 %) for 1 h, followed by incubation with primary
antibody rabbit polyclonal against the N-terminus of AR
(N20, Santa Cruz Biotech, Santa Cruz, CA) 1:500, rabbit
polyclonal against the C-terminus of PR (C19, Santa Cruz
Biotech, Santa Cruz, CA) 1:500 or rabbit polyclonal that rec-
ognizes the N-terminus of ER (H184, Santa Cruz Biotech,
Santa Cruz, CA) 1:500 overnight, followed by labeling with
anti-rabbit Alexa 568 (Invitrogen). After that, cells were in-
cubated with Alexa Fluor 488-phalloidin (Invitrogen). Sam-
ples were mounted in Pro Long with DAPI (Invitrogen).
Fig. 6 RU486 can rescue the increase of ADAMTS 1 and 4 induced by progesterone in ES-2 cell lysates but not in the conditioned medium. a and b
Representative Western blot of ADAMTS 1 and 4 in the lysates of ES-2 cells treated with progesterone (P) or progesterone and RU486 (P + RU486)
compared to control (C). c and d ADAMTS 1 and 4 protein expression in the lysates of ES-2 cells. e Representative Western blot of ADAMTS 1
and 4 in the conditioned medium from ES-2 cells treated as above. f and g ADAMTS 1 and 4 protein expression in the conditioned medium
from ES-2 cells. Conditioned medium equal sample loading was confirmed by Pounceau S staining (Additional file 1: Fig. S1d). Differences
among groups were considered statistically significant when p ≤ 0.05. Experiments were performed in triplicate
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Hormone treatment
NIH-OVCAR-3 and ES-2 cells were plated in 60-mm2
tissue culture dishes (Corning, New York, USA) at a
density of 3x106 cells per dish for Western Blot analyses
of total lysate and conditioned medium. Cells were
plated in 30-mm2 tissue culture dishes (Corning, New
York, USA) at a density of 1x106 cells per dish for RNA
extraction and qPCR analysis. In both cases, cells were
grown to 70 % of confluence, then washed with PBS and
cultured in phenol red-free Dulbecco’s Modified Eagle’s
Medium/F12 (DMEM-F12, Sigma), supplemented with
10 % charcoal-stripped fetal bovine serum for 24 h. After
this period, cells were treated with estrogen, progesterone
and testosterone (Sigma) in phenol red-free DMEM/F12
at the concentrations of 30nM, 1 μM, and 100 nM, re-
spectively, for 24 h. A group of NIH-OVCAR-3 and ES-2
cells treated with progesterone was also cultivated in the
presence of the progesterone inhibitor RU486 (7 μM).
Ovary cells lines cultivated without the addition of hor-
mones in phenol red-free DMEM/F-12 served as controls.
Treated and control cells were subjected to qPCR and
immunoblot analyses, to determine ADAMTS 1 and 4
mRNA and protein levels. All experiments were per-
formed in triplicate.
MTT cellular viability assay
After hormonal treatment for 24 h, the MTT assay was
performed. In summary, cell culture supernatants were
removed and a solution was added to each plate con-
taining 100 μl of fresh medium DMEM F12 with 10 μl
of an MTT solution (Calbiochem, Darmstadt, Germany)
of 5 mg/mL in PBS, resulting in a final MTT concentra-
tion of 0.5 mg/ml. Cells were maintained in the incuba-
tor for 3 h until blue crystals were formed. At this point,
DMSO (100 μl) was added to dissolve the crystals, the
plate was homogenized, and absorbance reading was
performed at 570 nm in a spectrophotometer.
Real-time PCR (qPCR)
Total RNA was extracted with the Magna Bead Total
RNA kit (Invitrogen, USA) following the manufacturer’s
recommendations. Ten micrograms of total RNA, previ-
ously treated with DNase, were reverse transcribed using
a High Capacity cDNA Archive Kit (Applied Biosystems,
Carlsbad, CA, USA). qPCR was performed using an Ap-
plied Biosystems 7500 Real-Time PCR System, and each
cDNA sample was analysed in duplicate. The PCR reac-
tions were carried out in a total volume of 25 μl according
to the manufacturer’s instructions for the SYBR Green
PCR Core reagent (Invitrogen, USA). The following PCR
primers were used: ADAMTS 1 forward, 5’-TGTGGTGT
TTGCGGGGGAAATG-3’ and reverse, 5’- TCGATGTTG
GTGGCTCCAGTT-3’; ADAMTS 4 forward, 5’ TCAGC
CTTCACTGCTGCTCAT-3’ and reverse 5’-GCCCATTC
AAACTGATGCATG 3’; and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) forward, 5’-CCTCCAAAATC
AAGTGGGGC G-3’ and reverse, 5’-GGGGCAGAGATG
ATGACCCTT-3’. As a result, the relative gene expression
was normalized, with GAPDH expression serving as the
internal control. Results were expressed as the n-fold
difference in target gene expression relative to the ex-
pression of the GAPDH gene and the reference sample.
The relative expression was calculated using the 2-ΔΔCT
method [32].
Cell fractionation
Nuclear–cytoplasmic fractionation was performed using
the NE-PER Nuclear and Cytoplasmic Extraction Reagents
kit (Thermo Fisher Scientific) according to the manufac-
turer’s protocol, and then quantified (BCA kit, Pierce).
Western blot
Western blots were carried out in order to compare
ADAMTS 1 and 4 levels in ES-2 and NIH-OVCAR-3
cell total lysates and conditioned medium and to analyse
steroid hormone receptors from fractions described above.
For the cell lysate protein preparation, cells were lysed in
RIPA buffer (150 mM NaCl, 1.0 % NP-40, 0.5 % deoxycho-
late, 0.1 % SDS, 50 mM Tris pH 8.0) containing a protease
inhibitor cocktail (Sigma). After centrifugation (10,000 g)
for 10 min at 4 °C, the supernatants were recovered and
quantified (BCA kit, Pierce). Protein from the conditioned
medium (1 mL) was obtained by ethanol precipitation.
For SDS-PAGE, 30 μg of protein from lysate and all pre-
cipitate from conditioned medium were loaded per well
and separated in 10 % polyacrylamide gel (prepared with
1.5 M Tris–HCl, 10 % SDS, 30 % bis-acrylamide, 10 %
ammonium persulfate, and TEMED). Gel contents were
transferred to a Hybond ECL nitrocellulose membrane
(Amersham), which was then blocked with TBS contain-
ing 5 % non-fat milk overnight at 4 °C. After a wash in
TBS with 0.05 % Tween 20 (TBST), the membranes
were probed with antibodies against ADAMTS 1 (1:1000,
Millipore MAB 1810), ADAMTS 4 (1:2000, Abcam
ab84792), AR (1:1000, N20, Santa Cruz Biotech), ER
(1:1000, H184, Santa Cruz Biotech ), PR (1:1000, C19,
Santa Cruz Biotech), Histone (1:4000, 05-457, Millipore),
GAPDH (1:4000, 9484, Abcam) or β-actin (1:2000, Sigma).
The ECL protocol was used to detect proteins on the
membrane.
Statistical analysis
Data were analysed with the Graph Pad Prism 5 software
(Graph Pad Software, Inc., San Diego, CA, USA), and
statistical significance was obtained using the One-way
Anova or T test.
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